Boostrix GlaxoSmithKline Biologicals - Treatment for Prevention of Diphtheria, Tetanus & Pertussis in Adolescents

Boostrix is indicated as a single dose active booster immunization against tetanus, diphtheria, and pertussis in individuals 10 through 18 years of age, thereby adding a pertussis component to the routine tetanus/diphtheria booster currently administered to teens.

Posted: May 2005

Related Articles:

Boostrix (tetanus, diphtheria, acellular pertussis vaccine (Tdap)) FDA Approval History

View comments

Hide
(web5)